Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 10 Jan 2026
Global CKD Burden Projected to Rise in Young Adults and Decline in Children by 2050
Read Full NewsThe rheumatology year in review highlights FDA approvals and pivotal data readouts.
Johnson & Johnson plans to initiate a phase 3 study based off the positive data.
Treatment with the orexin-receptor 2 agonist oveporexton was associated with improvements in attention, memory, and executive function in adults with narcolepsy type 1.
Those from the clinical community may expect to hear data from the registrational trial assessing zorevunersen in Dravet syndrome by mid-2027.
The FDA is expected to have a decision on efgartigimod as potentially the first approved therapy for seronegative myasthenia gravis by May 10, 2026.
Additional Phase 2 REVERT IPF Data Shows Greater Fibrosis Reduction With TTI-101
Bronchodilator Response Outperforms Genetic Risk in Predicting COPD Progression
1.
As EGFR internalization is decreased, BUB1 controls EGFR signaling.
2.
A paper strip test might enable the early detection of cancer.
3.
Breast cancer patients' arms swell less after an effective lymph node transfer.
4.
A First in Total Larynx Transplant; 'Sniffing' Out Lung Cancer; Gen X Cancer Toll
5.
For fit patients with CLL, frontline venetoclax-ibrutinib improves survival.
1.
CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target
2.
Integrating Immunotherapy and Staging Guidelines in Lung Cancer Treatment
3.
Seeing the Unseen: Examining Chancroid Through Images
4.
Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology
5.
Unveiling the Mystery of Epstein-Barr Virus: What We Know So Far
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC
2.
Navigating the Complexities of Ph Negative ALL - Part IV
3.
Virtual Case Study on Elephantiasis of Lower Limb- An Initiative by Hidoc Dr.
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge